Preventing Moderate to Severe Dermatologic Adverse Events in First-Line EGFR-Mutant Advanced NSCLC Treated With Amivantamab Plus Lazertinib: Early Success of the COCOON Trial

Alexander Spira, MD, PhD, FACP, FASCO​, and Randi Rabin, MPH, MSc,​ PA-C, discuss how proactive dermatologic adverse event management—specifically through the COCOON protocol—enhances treatment adherence, reduces toxicity, and improves quality of life for patients with EGFR-mutant non–small cell lung cancer receiving amivantamab plus lazertinib.